Hormonal
Obese women with Polycystic Ovary Syndrome (PCOS) have a significantly higher prevalence and severity of Obstructive Sleep Apnea (OSA) compared to age- and weight-matched controls, driven by elevated androgen levels and central obesity.
If you are an obese woman diagnosed with PCOS, you should be screened for Obstructive Sleep Apnea (OSA) even if you do not snore heavily. The risk is significantly higher than in other obese women due to hormonal factors. Ask your doctor for a sleep study if you experience daytime sleepiness or other symptoms.
Women with PCOS had a higher AHI than controls (22.5 6 6.0, vs. 6.7 6 1.0, P 5 0.008). Women with PCOS were also more likely to suffer from symptomatic OSA syndrome (44.4% vs. 5.5%, P 5 0.008).
Why this rating
Randomized controlled trial design with matched controls, though sample size is small (n=18 per group).
Source
Increased Prevalence of Obstructive Sleep Apnea Syndrome in Obese Women with Polycystic Ovary Syndrome<sup>1</sup>
Robert Fogel et al. · The Journal of Clinical Endocrinology & Metabolism · 2001
DOI 10.1210/jcem.86.3.7316
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →